Last reviewed · How we verify
Mannitol 20% Infusion
Mannitol is an osmotic diuretic that draws fluid from tissues into the intravascular space and increases urine output to reduce intracranial pressure and cerebral edema.
Mannitol is an osmotic diuretic that draws fluid from tissues into the intravascular space and increases urine output to reduce intracranial pressure and cerebral edema. Used for Reduction of intracranial pressure and cerebral edema, Acute kidney injury prevention, Glaucoma management.
At a glance
| Generic name | Mannitol 20% Infusion |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Drug class | Osmotic diuretic |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Mannitol functions as an osmotic agent that creates an osmotic gradient, pulling water from the interstitial and intracellular compartments into the plasma. This reduces brain edema and intracranial pressure by decreasing total brain water content. It is filtered by the glomerulus but poorly reabsorbed in the renal tubules, promoting osmotic diuresis and increased urine output.
Approved indications
- Reduction of intracranial pressure and cerebral edema
- Acute kidney injury prevention
- Glaucoma management
Common side effects
- Hypernatremia
- Dehydration
- Hypotension
- Rebound intracranial pressure elevation
- Electrolyte imbalance
Key clinical trials
- Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy (NA)
- Enhancing Renal Graft Function During Donor Anesthesia (NA)
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma (PHASE2)
- Intracolonic FODMAP Infusion in Healthy Volunteers (NA)
- Mannitol-induced Release of Copeptin in Healthy Adults and Patients With Polyuria-Polydipsia Syndrome (MARS Study) (NA)
- MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD) (PHASE2, PHASE3)
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (PHASE2, PHASE3)
- Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mannitol 20% Infusion CI brief — competitive landscape report
- Mannitol 20% Infusion updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Besancon portfolio CI